What do women know about early detection of breast cancer?

Breast cancer is the most common cancer in women in Europe: each year 350,000 new cases are diagnosed and each year about 130,000 women die of the disease. At the same time breast cancer is one of the few cancer types with encouraging healing prospects – if detected early.

Photo: What do women know about early detection of breast cancer?
Photo: What do women know about early detection of breast cancer?

What do we know about Breast Screening?

The results from the international Breast Cancer Awareness Survey, conducted by the GfK Group, are in and reveal interesting and helpful insights into how women perceive, deal with and feel about breast cancer prevention.

Over 4,000 women, between the ages of 25 and 65, from eight countries across the globe – the U.S.A., Germany, Brazil, China, Russia, India, Sweden, and Austria – took part in the survey. 500 women from each country provided statistical information regarding how they feel about the importance of breast cancer screening, their personal experiences, levels of trust with qualified doctors and channels of information, services, and official screening programs – all of which help to make us more aware and conscious about this topic. The results are in, and yield some very useful insights.

Based on the results from the international breast cancer awareness survey, we hold a panel discussion with professionals and representatives of various breast cancer organizations as well as patient representatives. Watch the outcomes of the panel discussion in 5 short videos.

For more information, also visit: www.siemens.com/pink

 

 

 

 

 

 

 

 

 

 

02.03.2011

Related articles

Photo

News • Possible biological explanation found

Why are dense breasts associated with increased cancer risk?

The risk of developing breast cancer is higher in breasts with high density. But why is that? Researchers at Linköping University have shown major biological differences that promote cancer growth.

Photo

News • Contrast-enhanced mammography vs. MRI

Neoadjuvant therapy response in breast cancer

Contrast-enhanced mammography (CEM) may be a useful alternative test for neoadjuvant therapy (NAT) response assessment in patients with breast cancer who are unable to undergo MRI.

Photo

Article •

Healthcare economics

Research using an analytical health economics model has suggested the current system of screening within the UK’s National Health Service (NHS) is only moderately likely to be cost effective.

Related products

Subscribe to Newsletter